GlassScriptPhysician profile
Deborah Skojac
NPI 1679667877
$2,290.72
in general payments reported to CMS, 2019-2025
25 companies · $675 in 2025
The $675 reported for 2025 was more than what 81% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.00 · 2022: $341 · 2023: $527 · 2024: $734 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $244.54 | 2022-2024 | Ojjaara |
| Merck Sharp & Dohme LLC | $194.67 | 2022-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $189.71 | 2023-2025 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $186.34 | 2021-2023 | Opdivo |
| Janssen Biotech, INC. | $181.06 | 2024-2025 | Rybrevant, Akeega, Erleada |
| Daiichi Sankyo INC. | $147.70 | 2024-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $144.56 | 2024-2025 | Monoferric |
| Abbvie INC. | $140.08 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $129.54 | 2022-2025 | Libtayo |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Seagen INC. | $115.35 | 2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $89.31 | 2023-2025 | |
| Stemline Therapeutics INC. | $67.13 | 2023 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $56.80 | 2022-2023 | Imbruvica |
| Pfizer INC. | $45.84 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.86 | 2025 | |
| Deciphera Pharmaceuticals INC. | $26.31 | 2024 | Qinlock |
| Medtronic, INC. | $26.30 | 2023 | Truclear |
| Hologic Sales and Service, LLC | $26.18 | 2025 | Aptima |
| Alexion Pharmaceuticals, INC. | $24.60 | 2024 | Ultomiris |
| Eisai INC. | $23.74 | 2023 | |
| Beone Medicines USA, INC. | $22.87 | 2025 | Tevimbra |
| Gilead Sciences, INC. | $22.03 | 2025 | |
| Lilly USA, LLC | $21.02 | 2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $15.84 | 2025 | Itovebi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Skojac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.